ARTICLE IN PRESS

Journal of Trace Elements in Medicine and Biology 22 (2008) 8192 www.elsevier.de/jtemb

INVITED REVIEW

Iodine requirements and the risks and benets of correcting iodine deciency in populations
Michael B. Zimmermanna,b,
a b

The Human Nutrition Laboratory, ETH Zu rich, Switzerland Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands

Received 4 February 2008; accepted 5 March 2008

Abstract
Iodine deciency has multiple adverse effects on growth and development due to inadequate thyroid hormone production that are termed the iodine deciency disorders (IDD). IDD remains the most common cause of preventable mental impairment worldwide. IDD assessment methods include urinary iodine concentration, goiter, thyroglobulin and newborn thyrotropin. In nearly all iodine-decient countries, the best strategy to control IDD is salt iodization, one of the most cost-effective ways to contribute to economic and social development. When salt iodization is not possible, iodine supplements can be targeted to vulnerable groups. Introduction of iodized salt to regions of chronic IDD may transiently increase the incidence of thyroid disorders, and programs should include monitoring for both iodine deciency and excess. Although more data on the epidemiology of thyroid disorders caused by differences in iodine intake are needed, overall, the relatively small risks of iodine excess are far outweighed by the substantial risks of iodine deciency. r 2008 Elsevier GmbH. All rights reserved.
Keywords: Iodine; Goiter; Thyroid; Cognition; Requirement

Contents Deciency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82 Diffuse goiter and mutinodular toxic goiter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82 Neurocognitive impairment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82 Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83 Assessment and diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84 Thyroid size . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85 Urinary iodine concentration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85 Thyroid stimulating hormone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86 Thyroglobulin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86 Treatment and prevention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87 Salt fortication with iodine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
Laboratory for Human Nutrition, Swiss Federal Institute of Technology Zurich, Schmelzbergstrasse 7, LFV E19, CH-8092 Zurich, Switzerland. Tel.: +41 44 632 8657; fax: +41 44 632 1470. E-mail address: michael.zimmermann@ilw.agrl.ethz.ch.

0946-672X/$ - see front matter r 2008 Elsevier GmbH. All rights reserved. doi:10.1016/j.jtemb.2008.03.001

ARTICLE IN PRESS
82 M.B. Zimmermann / Journal of Trace Elements in Medicine and Biology 22 (2008) 8192

Iodine supplementation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87 Excess and toxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90

Deciency
Iodine deciency (ID) has multiple adverse effects on growth and development in animals and humans. These are collectively termed the iodine deciency disorders (IDD) (Table 1), and are one of the most important and common human diseases [1,2]. They result from inadequate thyroid hormone production due to lack of sufcient iodine.

Diffuse goiter and mutinodular toxic goiter

Thyroid enlargement (goiter) is the classic sign of ID. It is a physiologic adaptation to chronic ID. As iodine intake falls, secretion of thyroid stimulating hormone (TSH) increases in an effort to maximize uptake of available iodine, and TSH stimulates thyroid hypertrophy and hyperplasia. Initially, goiters are characterized by diffuse, homogeneous enlargement, but over time, nodular goiter often develops. Many thyroid nodules
Table 1. The iodine deciency disorders, by age group (Refs. [1,2,65]) Age groups All ages Health consequences of iodine deciency Goiter, including toxic nodular goiter Increased occurrence of hypothyroidism in moderate-to-severe iodine deciency; decreased occurrence of hypothyroidism in mild-to-moderate iodine deciency Increased susceptibility of the thyroid gland to damage and thyroid cancer from iodine radioisotopes (e.g. from radioactive fall-out) Abortion Stillbirth Congenital anomalies Perinatal mortality Infant mortality Endemic cretinism Impaired mental function Delayed physical development Impaired mental function Iodine-induced hyperthyroidism Overall, moderate-to-severe iodine deciency causes subtle but widespread adverse effects in a population secondary to hypothyroidism, including decreased educability, apathy, and reduced work productivity, resulting in impaired social and economic development

derive from a somatic mutation and are of monoclonal origin [3]; the mutations appear to be more likely to result in nodules under the inuence of a growth promoter, such as ID. ID is associated with a high occurrence of multinodular toxic goiter, mainly seen in women older than 50 yr [4]. Large goiters may be cosmetically unattractive, can obstruct the trachea and esophagus, and may damage the recurrent laryngeal nerves and cause hoarseness. Surgery to reduce goiter has signicant risks, including bleeding and nerve damage, and hypothyroidism may develop after removal of thyroid tissue.

Neurocognitive impairment
Although goiter is the most visible effect of ID, the most serious adverse effect is damage to the fetus. Maternal thyroxine (T4) crosses the placenta before onset of fetal thyroid function at 1012 weeks and represents up to 2040% of T4 measured in cord blood at birth [5]. Normal levels of thyroid hormones are required for neuronal migration and myelination of the fetal brain, and lack of iodine irreversibly impairs brain development [6]. Severe ID during pregnancy increases risk for stillbirths, abortions, and congenital abnormalities [79]. Iodine treatment of pregnant women in areas of severe deciency reduces fetal and perinatal mortality and improves motor and cognitive performance of the offspring [10,11]. Severe ID in utero causes a condition characterized by gross mental retardation along with varying degrees of short stature, deaf mutism, and spasticity that is termed cretinism [1,2]. Two distinct types neurological and myxedematous have been described; it may also present as a mixed form. The more common, neurologic cretinism, has specic neurologic decits that include spastic quadriplegia with sparing of the distal extremities. The myxedematous form is seen most frequently in central Africa, and has the predominant nding of profound hypothyroidism, with thyroid atrophy and brosis. In areas of severe ID, cretinism can affect 515% of the population. Iodine prophylaxis has completely eliminated the appearance of new cases of cretinism in previously iodine-decient Switzerland and other countries, but it continues to occur in isolated areas of Western China [12]. The potential adverse effects of mild-to-moderate ID during pregnancy are unclear. Maternal subclinical hypothyroidism (an increased TSH in the second

Fetus

Neonate Child and adolescent Adults

ARTICLE IN PRESS
M.B. Zimmermann / Journal of Trace Elements in Medicine and Biology 22 (2008) 8192 83

trimester) and maternal hypothyroxinemia (a free T4 concentration o10 percentile at 12-weeks gestation) are associated with impaired mental and psychomotor development of the offspring [13,14]. However, in these studies, the maternal thyroid abnormalities were unlikely due to ID. In Europe, several randomized controlled trials of iodine supplementation in mild-tomoderately iodine-decient pregnant women have been done [15]. Iodine reduced maternal and newborn thyroid size, and, in some, decreased maternal TSH. However, none of the trials showed an effect on maternal and newborn total or free thyroid hormone concentrations, probably the best surrogate marker for healthy fetal development [16], and none measured long-term clinical outcomes, such as maternal goiter, thyroid autoimmunity, or child development. Although ID in utero impairs fetal growth and brain development, its postnatal effects on growth and cognition are less clear. Cross-sectional studies of moderate-to-severely iodine-decient children have generally reported impaired intellectual function and ne motor skills; two meta-analyses estimated that populations with chronic ID experience a reduction in IQ of 12.513.5 points [17,18]. However, observational studies are often confounded by other factors that affect child development, and these studies could not distinguish between the persistent effects of in utero ID and the effects of current iodine status. Several randomized trials have examined the impact of iodine supplementation on the cognitive performance of children, but their results are equivocal, and methodological problems limit their interpretation [19]. In a recent controlled trial in 1012-yr-old moderately iodine-decient Albanian children who received 400 mg of iodine as oral iodized oil or placebo, iodine treatment signicantly improved information processing, ne motor skills, and visual problem solving compared to placebo. Thus, in children born and raised in areas of ID, cognitive impairment is at least partially reversible by iodine repletion [19]. Data from cross-sectional studies on iodine intake and child growth are mixed, with most studies nding modest positive correlations [20]. In ve Asian countries, household access to iodized salt was correlated with increased weight-for-age and mid-upper-arm circumference in infancy [21]. However, controlled intervention studies of iodized oil alone and iodine given with other micronutrients have generally not found effects on child growth [20]. In iodine-decient children, impaired thyroid function and goiter are inversely correlated with insulin-like growth factor (IGF)-1 and insulin-like growth factor binding protein (IGFBP)-3 concentrations [22]. Recent controlled trials found iodine repletion increased IGF-1 and IGFBP-3 and improved somatic growth in children [20].

Overall, ID produces subtle but widespread adverse effects in a population, including decreased educability, apathy, and reduced work productivity, resulting in impaired social and economic development. Because mild-to-moderate ID affects up to 30% of the global population (see next section) and can impair cognition in children, ID is considered the most common cause of preventable mental retardation worldwide. The International Child Development Steering Group identied ID as one of four key global risk factors for impaired child development where the need for intervention is urgent [23].

Epidemiology
Only a few countries Switzerland, some of the Scandinavian countries, Australia, the US and Canada were completely iodine sufcient before 1990. Since then, globally, the number of households using iodized salt has risen from o20% to 470%, dramatically reducing ID [24]. This effort has been spurred by a coalition of international organizations, including ICCIDD, WHO, MI, and UNICEF, working closely with national IDD control committees and the salt industry; this informal partnership was established after the World Summit for Children in 1990. It has been funded by Kiwanis International, the Gates Foundation, and country aid programs. In 2007, WHO estimated nearly two billion individuals have an insufcient iodine intake, including 1/3 of all school-age children [25] (Table 2). The lowest prevalence of ID is in the Americas (10.6%), where the proportion of households consuming iodized salt is the highest in the world (E90%). The highest prevalence of ID is in Europe (52.0%), where the household coverage with iodized salt is the lowest (E25%), and many countries have weak or non-existent IDD control programs. The number of countries where ID remains a public health problem is 47. However, there has been progress since 2003: 12 countries have progressed to optimal iodine status and the percentage of school-aged children at risk of iodine deciency has decreased by 5% (Fig. 1). However, iodine intake is more than adequate, or even excessive, in 34 countries, an increase from 27 in 2003 [25]. In Australia and the US, two countries previously iodine sufcient, iodine intakes are falling. Australia is now mildly iodine decient [26], and in the US, the median UI is 145 mg/L, still adequate but half the median value of 321 mg/L found in the 1970s [27]. These changes emphasize the importance of regular monitoring of iodine status in countries, to detect both low and excessive intakes of iodine. There are several limitations to these WHO prevalence data. First, extrapolation from a population

ARTICLE IN PRESS
84 M.B. Zimmermann / Journal of Trace Elements in Medicine and Biology 22 (2008) 8192

Table 2. Prevalence of iodine deciency, as total number (millions) and percentages, in general population (all age groups) and in school-age children (612 yr) in 2007 (Ref. [25]) and the % of households with access to iodized salt (Ref. [67]) WHO regionsa Population with urinary iodine o100 mg/Lb General population Africa Americas Eastern Mediterranean Europe Southeast Asia Western Pacic Total
a b

% of households with access to iodized saltc 66.6 86.8 47.3 49.2 61.0 89.5 70.0

School-age children 57.7 11.6 43.3 38.7 73.1 41.6 263.7 (40.8%) (10.6%) (48.8%) (52.4%) (30.3%) (22.7%) (31.5%)

312.9 98.6 259.3 459.7 503.6 374.7 2000.0

(41.5%) (11.0%) (47.2%) (52.0%) (30.0%) (21.2%) (30.6%)

193 WHO Member States. Based on population estimates for 2006 (United Nations, Population Division, World Population Prospects: the 2004 revision). c These gures do not include data for non-UNICEF countries (e.g., the US and Western Europe).

70
2003

60 50 Percentage 40 30 20 10 0
rra
Af

2007

ne

ric

an

a Am

er

ica

r Eu

op

ed

Ea

st er

u So

th

-E

ite

t as

As

ia te es W rn Pa

ci

fic G

lo

ba

WHO Region

Fig. 1. Change in the prevalence of iodine deciency in school-age children (dened as a urinary iodine concentration o100 mg/L) by WHO region and globally, between 2003 and 2007 (data from Ref. [25]).

indicator (median UI) to dene the number of individuals affected is problematic, e.g. a country in which children have a median UI of 100 mg/L would be classied as being iodine sufcient, yet at the same time 50% of children would be classied as having inadequate iodine intakes. Second, nationally representative surveys represent only 60% of the global population included in the WHO data, and sub-national data may under or overestimate the extent of ID [25]. Finally, there are insufcient data from nearly all countries to estimate the prevalence of ID in pregnant women.

Assessment and diagnosis

Recommendations for iodine intake for different age groups are shown in Table 3. Four methods are generally recommended for assessment of iodine nutrition in populations: urinary iodine concentration (UI), the goiter rate, TSH, and thyroglobulin (Tg). These indicators are complementary, in that UI is a sensitive indicator of recent iodine intake (days) and Tg shows an intermediate response (weeks to months), whereas changes in the goiter rate reect long-term iodine nutrition (months to years).

ARTICLE IN PRESS
M.B. Zimmermann / Journal of Trace Elements in Medicine and Biology 22 (2008) 8192 85

Table 3.

Recommendations for iodine intake (mg/day) by age or population group US Institute of Medicine (Ref. [34]) 110130 90 120 150 220 290 Age or population groupb Children 05 yr Children 612 yr Adults 412 yr Pregnancy Lactation World Health Organization (Refs. [1,51]) 90 120 150 250 250

Age or population groupa Infants 012 monthsc Children 18 yr Children 913 yr Adults X14 yr Pregnancy Lactation
a

Recommended daily allowance. Recommended nutrient intake. c Adequate intake.

b

Thyroid size
Two methods are available for measuring goiter: neck inspection and palpation, and thyroid ultrasonography. Goiter surveys are usually done in school-age children. By palpation, a thyroid is considered goitrous when each lateral lobe has a volume greater than the terminal phalanx of the thumbs of the subject being examined. In the classication system of WHO (1), grade 0 is dened as a thyroid that is not palpable or visible, grade 1 is a goiter that is palpable but not visible when the neck is in the normal position (i.e., the thyroid is not visibly enlarged), and grade 2 goiter is a thyroid that is clearly visible when the neck is in a normal position. Palpation of goiter in areas of mild ID has poor sensitivity and specicity; in such areas, measurement of thyroid volume by ultrasound is preferable for classifying goiter [28]. Portable ultrasound equipment can be used in the eld, and goiter classied according to international reference criteria for iodinesufcient children by age, gender, and body surface area [29]. The total goiter rate is used to dene severity using the following criteria: o5%, iodine sufciency; 5.019.9%, mild deciency; 20.029.9%, moderate deciency; and 430%, severe deciency [1]. In areas of endemic goiter, although thyroid size predictably decreases in response to increases in iodine intake, thyroid size may not return to normal for months or years after correction of ID [30]. During this transition period, the goiter rate is difcult to interpret, because it reects both a populations history of iodine nutrition and its present status. A sustained salt iodization program will decrease the goiter rate by ultrasound to o5% in school-age children [31] and this indicates disappearance of ID as a signicant public health problem [1].

Urinary iodine concentration

Because 490% of ingested iodine is excreted in the urine, UI is an excellent indicator of recent

iodine intake. Most methods of measuring UI are based on the SandellKolthoff reaction, in which iodide catalyzes the reduction of yellow ceric ammonium sulfate to the colorless cerous form, in the presence of arsenious acid. UI can be expressed as a concentration (mg/L), in relationship to creatinine excretion (mg iodine/g creatinine), or as 24-h excretion (mg/day). For populations, because it is impractical to collect 24-h samples in eld studies, UI can be measured in spot urine specimens from a representative sample of the target group, and expressed as the median, in mg/L [1]. Variations in hydration among individuals generally even out in a large number of samples, so that the median UI in spot samples correlates well with that from 24-h samples. For national, school-based surveys of iodine nutrition, the median UI from a representative sample of spot urine collections from E1200 children (30 sampling clusters 40 children per cluster) can be used to classify a populations iodine status [1] (Table 4). However, the median UI is often misinterpreted. Individual iodine intakes, and, therefore, spot UI concentrations are highly variable from day-to-day [32], and a common mistake is to assume that all subjects with a spot UIo100 mg/L are iodine decient. To estimate iodine intakes in individuals, 24-h collections are preferable, but difcult to obtain. An alternative is to use the age- and sex-adjusted iodine: creatinine ratio in adults, but this also has limitations [33]. Creatinine may be unreliable for estimating daily iodine excretion from spot samples, especially in malnourished subjects where creatinine concentration is low. Daily iodine intake for population estimates can be extrapolated from UI, using estimates of mean 24-h urine volume and assuming an average iodine bioavailability of 92% using the formula: Urinary iodine (mg/L) 0.0235 body weight (kg) daily iodine intake [34]. Using this formula, a median UI of 100 mg/L corresponds roughly to an average daily intake of 150 mg.

ARTICLE IN PRESS
86 M.B. Zimmermann / Journal of Trace Elements in Medicine and Biology 22 (2008) 8192

Table 4. Epidemiological criteria for assessing iodine nutrition in a population based on median and/or range of urinary iodine concentrations (Refs. [1,51]) Median urinary iodine (mg/L) School-aged children o20 2049 5099 100199 200299 4300 Pregnant women o150 150249 250499 X500 Lactating womenb o100 X100 Children less than 2 yr old o100 X100
a b

Iodine intake

Iodine nutrition

Insufcient Insufcient Insufcient Adequate More than adequate Excessive

Severe iodine deciency Moderate iodine deciency Mild iodine deciency Optimal Risk of iodine-induced hyperthyroidism in susceptible groups Risk of adverse health consequences (iodine-induced hyperthyroidism, autoimmune thyroid disease)

Insufcient Adequate More than adequate Excessivea Insufcient Adequate Insufcient Adequate

The term excessive means in excess of the amount required to prevent and control iodine deciency. In lactating women, the gures for median urinary iodine are lower than the iodine requirements because of the iodine excreted in breast milk.

Thyroid stimulating hormone

Because serum TSH is determined mainly by the level of circulating thyroid hormone, which in turn reects iodine intake, TSH can be used as an indicator of iodine nutrition. However, in older children and adults, although serum TSH may be slightly increased by ID, values often remain within the normal range. TSH is therefore a relatively insensitive indicator of iodine nutrition in adults [1]. In contrast, TSH is a sensitive indicator of iodine status in the newborn period [35]. Compared to the adult, the newborn thyroid contains less iodine but has higher rates of iodine turnover. Particularly when iodine supply is low, maintaining high iodine turnover requires increased TSH stimulation. Serum TSH concentrations are therefore increased in iodine-decient infants for the rst few weeks of life, a condition termed transient newborn hypothyroidism. In areas of ID, an increase in transient newborn hypothyroidism, indicated by 43% of newborn TSH values above the threshold of 5 mU/L whole blood collected 34 days after birth, suggests ID in the population [30,36]. TSH is used in many countries for routine newborn screening to detect congenital hypothyroidism. If already in place, such screening offers a sensitive indicator of iodine nutrition [1]. Newborn TSH is an important measure because it reects iodine status

during a period when the developing brain is particularly sensitive to ID.

Thyroglobulin
Tg is synthesized only in the thyroid, and is the most abundant intrathyroidal protein [37]. In iodine sufciency, small amounts of Tg are secreted into the circulation, and serum Tg is normally o10 mg/L. In areas of endemic goiter, serum Tg increases due to greater thyroid cell mass and TSH stimulation. Serum Tg is well correlated with the severity of ID as measured by UI [38]. Tg can also be assayed on dried blood spots taken by a nger prick [39,40], simplifying collection and transport. In prospective studies, dried blood spot Tg has been shown to be a sensitive measure of iodine status and reects improved thyroid function within several months after iodine repletion [39,40]. An international reference range and a reference standard is now available; the reference interval in iodinesufcient children is 440 mg/L [40]. In contrast, thyroid hormone concentrations are poor indicators of iodine status. In iodine-decient populations, serum T3 increases or remains unchanged, and serum T4 usually decreases. However, these changes are often within the normal range, and the overlap with

ARTICLE IN PRESS
M.B. Zimmermann / Journal of Trace Elements in Medicine and Biology 22 (2008) 8192 87

DALYs Lost (thousands)

800 600 400 200 0

si P a/ ac ific C e/ en l tra As ia t La in Am er ica /N st or th Af ric a So h ut As ia a ah ra n
66 409 381 366

748

83

Af

ric

A E.

r Eu

op

.E

Su

b-

Fig. 2. Disability-adjusted life years (DALYs) (thousands) lost due to iodine deciency among children under age 5, by region. A DALY is calculated as the present value of the future years of disability-free life that are lost as a result of the premature deaths or cases of disability occurring in a particular year (data from Ref. [44]).

iodine-sufcient populations is large enough to make thyroid hormone levels an insensitive measure of iodine nutrition [1].

Treatment and prevention

Salt fortication with iodine
In nearly all regions affected by ID, the most effective way to control ID is through salt iodization [1]. Universal salt iodization (USI) is a term used to describe the iodization of all salts for human (food industry and household) and livestock consumption. Although the ideal, even in countries with successful salt iodization programs, USI is rarely achieved, as food industries are often reluctant to use iodized salt, and many countries do not iodize salt for livestock. WHO/UNICEF/ICCIDD recommends that iodine is added at a level of 2040 mg iodine/kg salt, depending on local salt intake [1]. Iodine can be added to salt in the form of potassium iodide (KI) or potassium iodate (KIO3). Because KIO3 has higher stability than KI in the presence of salt impurities, humidity, and porous packaging [41,42], it is the recommended form in tropical countries and those with low-grade salt. Iodine is usually added after the salt has been dried. Two techniques are used: (1) the wet method, where a solution of KIO3 is dripped or sprayed at a regular rate on to salt passing by on a conveyor belt; (2) the dry method, where KI or KIO3 powder is sprinkled over the dry salt. Optimally, packaging should be in low-density polyethylene bags. In a multi-country study, high humidity combined with porous packing resulted in up to 90% losses of iodine in 1 yr of storage in high-density polyethylene bags, compared to 1015% from lowdensity polyethylene bags [42].

Salt iodization remains the most cost-effective way of delivering iodine and of improving cognition in iodinedecient populations [43]. Worldwide, the annual costs of salt iodization are estimated at 0.020.05 US$ per child covered, and the costs per child death averted are US$1000 and per disability-adjusted life year (DALY) gained are US$3436 US (Fig. 2) [44]. Looked at in another way, prior to widespread salt iodization, the annual potential losses attributable to ID in the developing world have been estimated to be US$35.7 billion as compared with an estimated US$0.5 billion annual cost for salt iodization, i.e., a 70:1 benet:cost ratio [45]. The World Bank [46] strongly recommends that governments invest in micronutrient programs, including salt iodization, to promote development, concluding: Probably no other technology offers as large an opportunity to improve lives at such low cost and in such a short time.

Iodine supplementation
In some regions, iodization of salt may not be practical for control of ID, at least in the short term. This may occur in remote areas where communications are poor or where there are numerous small-scale salt producers. In these areas, iodized oil supplements can be used [1]. Iodized oil is prepared by esterication of the unsaturated fatty acids in seed or vegetable oils, and addition of iodine to the double bonds. It can be given orally or by intramuscular injection [47]. The intramuscular route has a longer duration of action, but oral administration is more common because it is simpler. Usual doses are 200400 mg iodine/yr and it is often targeted to women of child-bearing age, pregnant women, and children [10,11] (Table 5). Iodized oil given in the rst and second trimesters of pregnancy decreased the prevalence of neurological abnormalities and

ARTICLE IN PRESS
88 M.B. Zimmermann / Journal of Trace Elements in Medicine and Biology 22 (2008) 8192

Table 5. Recommendations for iodine supplementation in pregnancy and infancy in areas where o90% of households are using iodized salt and the median UI is o100 mg/L in schoolchildren (Ref. [51]) Women of childbearing age A single annual oral dose of 400 mg of iodine as iodized oil Or A daily oral dose of iodine as potassium iodide should be given so that the total iodine intake meets the RNIa of 150 mg/day of iodine A single annual oral dose of 400 mg of iodine as iodized oil Or A daily oral dose of iodine as potassium iodide should be given so that the total iodine intake meets the new RNI of 250 mg/day iodine Iodine supplements should not be given to a woman who has already been given iodized oil during her current pregnancy or up to 3 months before her current pregnancy started A single oral dose of 100 mg of iodine as iodized oil Or A daily oral dose of iodine as potassium iodide should be given so that the total iodine intake meets the RNI of 90 mg/day of iodine Should be given iodine supplements only if the mother was not supplemented during pregnancy or if the child is not being breast-fed A single annual oral dose of 200 mg of iodine as iodized oil as soon as possible after reaching 7 months of age Or A daily oral dose of iodine as potassium iodide should be given so that the total iodine intake meets the RNI of 90 mg/day of iodine

Women who are pregnant or lactating

developing countries and offer another simple way to deliver iodine locally. Whether providing preterm infants with supplemental iodine prevents morbidity and mortality is uncertain [50]. In countries or regions where a salt iodization program covers X90% of households and has been sustained for X2 yr, and the median UI indicates iodine sufciency (Table 4), pregnant and lactating women do not need iodine supplementation [51]. In iodine-decient countries or regions that have weak iodized salt distribution, supplements should be given to pregnant women, lactating women and infants, according to the strategy shown in Table 5 [51].

Excess and toxicity

Acute iodine poisoning caused by ingestion of many grams causes gastrointestinal irritation, abdominal pain, nausea, vomiting, and diarrhea, as well as cardiovascular symptoms, coma, and cyanosis [52]. Excess iodine intake may very rarely precipitate iodermia, a skin disorder consisting of acneiform eruptions, pruritic rash, and urticaria [53]. In areas of iodine sufciency, healthy individuals are remarkably tolerant to iodine intakes up to 1 mg per day, as the thyroid is able to adjust to a wide range of intakes to regulate the synthesis and release of thyroid hormones [54]. However, doses of iodine in the mg range may cause hypothyroidism in those with damaged thyroid glands because normal down-regulation of iodine transport into the gland does not occur. Individuals with nodular goiter may also respond adversely to intakes lower than 1 mg/day. In children, chronic intakes of X500 mg/day are associated with increased thyroid volume, an early sign of thyroid dysfunction [55]. European [56] and USA [34] expert committees have recommended tolerable upper intake levels for iodine (Table 6), but caution that individuals with chronic ID may respond adversely to intakes lower than these. In monitoring populations consuming iodized salt, the WHO/UNICEF/ICCIDD recommendations for the median UI that indicates more than adequate and excess iodine intake are shown in Table 4. An increase in iodine intake of populations with chronic ID may precipitate iodine-induced hyperthyroidism (IIH) [57]. It has been reported in the introductory phase of several USI programs, including an outbreak in Zimbabwe and the DR of the Congo due to excessively iodized salt. IIH primarily affects older adults with longstanding nodular goiter whose iodine intake is rapidly increased. Thyrocytes in nodules often become insensitive to TSH control, and if iodine supply is suddenly increased, these autonomous nodules may overproduce thyroid hormone [58]. Symptoms of IIH include weight loss, tachycardia, muscle weakness, and

Children aged 06 months

Children aged 724 months old

Recommended nutrient intake.

improved developmental test scores through 7 yr, compared with supplementation later in pregnancy or treatment after birth [48]. Its disadvantages are an uneven level of iodine in the body over time and the need for direct contact with individuals with the accompanying increased costs. Iodine can also be given as KI or KIO3 as drops or tablets. Single oral doses of potassium iodide monthly (30 mg) or biweekly (8 mg) can provide adequate iodine for school-age children [49]. Lugols iodine, containing E6 mg iodine per drop, and similar preparations are often available as antiseptics in rural dispensaries in

ARTICLE IN PRESS
M.B. Zimmermann / Journal of Trace Elements in Medicine and Biology 22 (2008) 8192 89

Table 6.

Tolerable upper intake level for iodine (mg/day) European Commission/Scientic Committee on Food (Ref. [56]) 200 250 300 450 500 600 600 US Institute of Medicine (Ref. [34]) 200 300 300 300 900 1100 1100

Age group

13 yr 46 yr 710 yr 1114 yr 1517 yr Adult Pregnant women

skin warmth, without the ophthalmopathy of Graves disease. It is nearly always transient and its incidence reverts to baseline after 110 yr of intervention. However, it is dangerous when superimposed on underlying heart disease, and may be lethal [57]. IIH prevention includes careful monitoring of salt iodine levels and training of regional health staff in IIH identication and treatment. To investigate the effects of iodine intake on thyroid disorders in China [59,60], a 5-yr, prospective community-based survey was done in three rural Chinese communities with mild-decient, more than adequate (previously mild ID corrected by iodized salt), and excessive iodine intake from environmental sources; the median UI was 88, 214, and 634 mg/L, respectively. For the three communities, the cumulative incidence of hyperthyroidism was 1.4%, 0.9%, and 0.8%; of overt hypothyroidism, 0.2%, 0.5%, and 0.3%; of subclinical hypothyroidism, 0.2%, 2.6%, and 2.9%; and of autoimmune thyroiditis, 0.2%, 1.0%, and 1.3%, respectively. In most individuals, these later two disorders were not sustained. Among subjects with euthyroidism and antithyroid antibodies at baseline, the 5-yr incidence of elevated serum thyrotropin levels was greater among those with more than adequate or excessive iodine intake than among those with mildly decient iodine intake. In all three communities, independent of iodine intake, either positive TPOAb (OR 4.2 (95% CI 1.78.8) or goiter (OR 3.1 (95% CI 1.46.8) in original healthy participants was associated with the occurrence of hyperthyroidism. Denmark has documented the pattern of thyroid disease after careful introduction of iodized salt [61,62]. New cases of overt hypothyroidism were identied in two areas of Denmark with previous moderate and mild ID, respectively (Aalborg, median UI 45 mg/L; and Copenhagen, median UI 61 mg/L) before and for the rst 7 yr after introduction of a national program of salt iodization. The overall incidence rate of hypothyroidism modestly increased during the study period: baseline,

38.3/100,000 yr; after salt iodization, 47.2/100,000 (vs. baseline, RR 1.23; 95% CI 1.071.42). There was a geographic difference because hypothyroidism increased only in the area with previous moderate ID. The increase occurred in young and middle-aged adults. Similarly, new cases of overt hyperthyroidism in these two areas of Denmark before and for the rst 6 yr after iodine fortication were identied [62]. The overall incidence rate of hyperthyroidism increased [baseline, 102.8/100,000/yr; after salt iodization 138.7/100,000 (P for trend o0.001)]. Hyperthyroidism increased in both sexes and in all age groups, but in contrast to IIH where most cases occur in older individuals, many of the new cases were observed in young subjects the increase was highest in adults aged 2039 yr and were presumably of autoimmune origin. The authors suggested that further monitoring is expected to show a decrease in the number of elderly subjects suffering from nodular hyperthyroidism. The overall incidence of differentiated thyroid carcinoma in populations does not appear to be inuenced by iodine intake. A study in Denmark suggested modest differences in iodine intake between regions did not affect thyroid cancer incidence or the distribution of its subtypes [63]. However, other studies have suggested the distribution of the subtypes of thyroid carcinoma is related to iodine intake; in areas of higher iodine intake, there appear to be fewer of the more aggressive follicular and anaplastic carcinomas, but more papillary carcinomas [64]. When iodine prophylaxis is introduced in populations, there may be an increase in the ratio of papillary to follicular carcinoma, and this shift toward less malignant types of thyroid cancer, as well as a lower radiation dose to the thyroid in case of nuclear fallout, are benets of the correction of mild-tomoderate ID [65].

Conclusions
Concerns about potential increases in iodine-induced thyroid disease continue to delay or limit the implementation of iodine prophylaxis in iodine-decient populations. Are these concerns justied? Looking at the benets vs. the risks of iodine prophylaxis, it is clear that severe ID in pregnancy can cause hypothyroidism, poor pregnancy outcome, cretinism, and irreversible mental retardation. Mild-to-moderate ID in utero and in childhood results in less-severe learning disability, poor growth, and diffuse goiter. In adults, mild-to-moderate ID appears to be associated with higher rates of more aggressive subtypes of thyroid cancer, and increases risk for nontoxic and toxic nodular goiter and associated hyperthyroidism. However, increasing iodine intakes in decient populations is not without risk. Mild ID may be associated with a decreased risk of overt and subclinical

ARTICLE IN PRESS
90 M.B. Zimmermann / Journal of Trace Elements in Medicine and Biology 22 (2008) 8192

hypothyroidism, as well as autoimmune thyroiditis. In China, chronic excess iodine intakes are associated with a small increase in subclinical hypothyroidism and autoimmune thyroiditis, but not overt hypo- or hyperthyroidism. In contrast, in Denmark, correcting mild-to-moderate deciency modestly increased rates of hypo- and hyperthyroidism. The differing effects of varying iodine intakes in these studies may be related to differences in underlying thyroid autonomy, genetic susceptibility or other environmental variables. It is possible that nutritional determinants of thyroid function (e.g. selenium, vitamin A, iron) differ in the populations studied. More prospective data on the epidemiology of thyroid disorders caused by changes in iodine intake in other countries would be valuable. Clearly, programs of iodine prophylaxis need to carefully monitor for both ID and excess. Overall, the relatively small risks of iodine excess are far outweighed by the substantial risks of iodine deciency pregnancy loss, goiter, and mental retardation [66], which continue to affect up to a 1/3rd of the global population [25,67].

References
[1] World Health Organization/International Council for the Control of the Iodine Deciency Disorders/United Nations Childrens Fund (WHO/ICCIDD/UNICEF). Assessment of the iodine deciency disorders and monitoring their elimination. 2nd edition. Geneva: WHO; 2007. [2] Delange F, Hetzel B. The iodine deciency disorders. In: DeGroot LE, Hannemann G, editors. The thyroid and its diseases. Available at: /http://www.thyroidmanager.org/S. Accessed January 18, 2008. [3] Kopp P, Kimura ET, Aeschimann S, Oestreicher M, Tobler A, Fey MF, et al. Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters. J Clin Endocrinol Metab 1994;79(1):1349. [4] Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med 1991; 229:41520. [5] Sack J. Thyroid function in pregnancy maternalfetal relationship in health and disease. Pediatr Endocrinol Rev 2003;1(Suppl. 2):1706. [6] Morreale de Escobar G, Obregon MJ, Escobar del Rey F. Role of thyroid hormone during early brain development. Eur J Endocrinol 2004;151(Suppl. 3):U2537. [7] Pharoah POD, Butteld IH, Hetzel BS. Neurological damage to the fetus with severe iodine deciency during pregnancy. Lancet 1971;i:30810. [8] Dillon JC, Milliez J. Reproductive failure in women living in iodine decient areas of West Africa. Br J Obstet Gynaecol 2000;107:6316.

[9] Cobra C, Muhilal, Rusmil K, Rustama D, Djatnika, Suwardi SS, et al. Infant survival is improved by oral iodine supplementation. J Nutr 1997;127:5748. [10] Cao XY, Jiang XM, Dou ZH, Rakeman MA, Zhang ML, ODonnell K, et al. Timing of vulnerability of the brain to iodine deciency in endemic cretinism. N Engl J Med 1994;331:173944. [11] Connolly KJ, Pharoah PO, Hetzel BS. Fetal iodine deciency and motor performance during childhood. Lancet 1979;2:114951. [12] Chen ZP. New cretins discovered in southern Xinjiang, China. IDD Newslett. 2007;23(1):18. [13] Pop VJ, Kuijpens JL, van Baar AL, Verkerk G, van Son MM, de Vijlder JJ, et al. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. Clin Endocrinol (Oxf) 1999;50:14955. [14] Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, et al. Maternal thyroid deciency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999;341:54955. [15] Zimmermann MB. The adverse effects of mild-tomoderate iodine deciency during pregnancy and childhood: a review. Thyroid 2007;17:82935. [16] Pop VJ, Vulsma T. Maternal hypothyroxinaemia during (early) gestation. Lancet 2005;365(9471):16046. [17] Bleichrodt N, Garcia I, Rubio C, Morreale de Escobar G, Escobar del Rey F. Developmental disorders associated with severe iodine deciency. In: Hetzel B, Dunn J, Stanbury J, editors. The prevention and control of iodine deciency disorders. Amsterdam: Elsevier; 1987. p. 6584. [18] Qian M, Wang D, Watkins WE. The effects of iodine on intelligence in children: a meta-analysis of studies conducted in China. Asia Pac J Clin Nutr 2005;14:3242. [19] Zimmermann MB, Connolly K, Bozo M, Bridson J, Rohner F, Grimci L. Iodine supplementation improves cognition in iodine-decient schoolchildren in Albania: a randomized, controlled, double-blind study. Am J Clin Nutr 2006;83:10814. [20] Zimmermann MB, Jooste PL, Mabapa NS, Mbhenyane X, Schoeman S, Biebinger R, et al. Treatment of iodine deciency in school-age children increases insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations and improves somatic growth. J Clin Endocrinol Metab 2007;92(2):43742. [21] Mason JB, Deitchler M, Gilman A, Gillenwater K, Shuaib M, Hotchkiss D, et al. Iodine fortication is related to increased weight-for-age and birthweight in children in Asia. Food Nutr Bull 2002;23:292308. [22] Wan Nazaimoon WM, Osman A, Wu LL, Khalid BA. Effects of iodine deciency on insulin-like growth factorI, insulin-like growth factor-binding protein-3 levels and height attainment in malnourished children. Clin Endocrinol 1996;45:7983. [23] Delange F, Bu rgi H, Chen ZP, Dunn JT. World status of monitoring iodine deciency disorders control programs. Thyroid 2002;12(10):91524. [24] Walker SP, Wachs TD, Gardner JM, Lozoff B, Wasserman GA, Pollitt E, et al. International child development steering group. Child development: risk factors for

ARTICLE IN PRESS
M.B. Zimmermann / Journal of Trace Elements in Medicine and Biology 22 (2008) 8192 91

[25]

[26]

[27]

[28]

[29]

[30]

[31]

[32]

[33]

[34]

[35]

[36]

[37]

adverse outcomes in developing countries. Lancet 2007;369(9556):14557. WHO Global Database on Iodine Deciency. Available at: http://www.who.int/whosis/databaseS. Accessed January 14, 2008. Li M, Eastman CJ, Waite KV, Ma G, Zacharin MR, Topliss DJ, et al. Are Australian children iodine decient? Results of the Australian National Iodine Nutrition Study. Med J Aust 2006;184(4):1659. Caldwell KL, Jones R, Hollowell JG. Urinary iodine concentration: United States National Health and Nutrition Examination Survey 20012002. Thyroid 2005;15: 6929. Zimmermann M, Saad A, Hess S, Torresani T, Chaouki N. Thyroid ultrasound compared with World Health Organization 1960 and 1994 palpation criteria for determination of goiter prevalence in regions of mild and severe iodine deciency. Eur J Endocrinol 2000;143(6): 72731. Zimmermann MB, Hess SY, Molinari L, et al. New reference values for thyroid volume by ultrasound in iodine-sufcient schoolchildren: a WHO/NHD Iodine Deciency Study Group Report. Am J Clin Nutr 2004;79: 2317. Zimmermann MB, Hess SY, Adou P, et al. Thyroid size and goiter prevalence after introduction of iodized salt: a 5-yr prospective study in schoolchildren in Co te dIvoire. Am J Clin Nutr 2003;77:6637. Zimmermann MB, Aeberi I, Torresani T, Bu rgi H. Increasing the iodine concentration in the Swiss iodized salt program markedly improves iodine status in pregnant women and children: a 5-yr prospective national study. Am J Clin Nutr 2005;88:38892. Andersen S, Karmisholt J, Pedersen KM, Laurberg P. Reliability of studies of iodine intake and recommendations for number of samples in groups and in individuals. Br J Nutr 2007;26:16 [Epub]. Knudsen N, Christiansen E, Brandt-Christensen M, Nygaard B, Perrild H. Age- and sex-adjusted iodine/ creatinine ratio. A new standard in epidemiological surveys? Evaluation of three different estimates of iodine excretion based on casual urine samples and comparison to 24 h values. Eur J Clin Nutr 2000;54:3613. Institute of Medicine, Academy of Sciences, USA. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium and zinc. Washington, DC: National Academy Press; 2001. Delange F. Neonatal screening for congenital hypothyroidism: results and perspectives. Horm Res 1997;48: 5161. World Health Organization/International Council for the Control of the Iodine Deciency Disorders/United Nations Childrens Fund. Indicators for assessing iodine deciency disorders and their control through salt iodization. WHO/NUT/94.6. Geneva: WHO; 1994. Rousset BA, Dunn JT. Thyroid hormone synthesis and secretion. In: DeGroot LE, Hennemann G, editors. The thyroid and its diseases. Available at: /http://www. thyroidmanager.org/S. Accessed January 18, 2008.

[38] Knudsen N, Bu low I, Jorgenson T, et al. Serum thyroglobulin a sensitive marker of thyroid abnormalities and iodine deciency in epidemiologic studies. J Clin Endocrinol Metab 2001;86:3599603. [39] Zimmermann MB, Moretti D, Chaouki N, Torresani T. Development of a dried whole blood spot thyroglobulin assay and its evaluation as an indicator of thyroid status in goitrous children receiving iodized salt. Am J Clin Nutr 2003;77:14538. [40] Zimmermann MB, de Benoist B, Corigliano S, Jooste PL, Molinari L, Moosa K, et al. Assessment of iodine status using dried blood spot thyroglobulin: development of reference material and establishment of an international reference range in iodine-sufcient children. J Clin Endocrinol Metab 2006;91(12):48817. [41] Diosady LL, Alberti JO, Mannar MGV, Stone TJ. Stability of iodine in iodized salt used for correction of iodine-deciency disorders, I. Food Nutr Bull 1997;18: 38896. [42] Diosady LL, Alberti JO, Mannar MGV, FitzGerald S. Stability of iodine in iodized salt used for correction of iodine-deciency disorders, II. Food Nutr Bull 1998;19: 24050. [43] Engle PL, Black MM, Behrman JR, Cabral de Mello M, Gertler PJ, Kapiriri L, et al. International Child Development Steering Group. Strategies to avoid the loss of developmental potential in more than 200 million children in the developing world. Lancet 2007;369(9557):22942. [44] Cauleld LE, Richard SA, Rivera JA, Musgrove P, Black RE. Stunting, wasting, and micronutrient deciency disorders 2006. In: Dean T, Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease control priorities in developing countries. 2nd ed. New York: Oxford University Press; 2006. p. 55168. [45] Horton S. The economics of food fortication. J Nutr 2006;136(4):106871. [46] McGuire J, Galloway R. Enriching lives. Overcoming vitamin and mineral malnutrition in developing countries. Washington, DC: World Bank; 1994. [47] Benmiloud M, Chaouki ML, Gutekunst R, Teichert HM, Wood WG, Dunn JT. Oral iodized oil for correcting iodine deciency: optimal dosing and outcome indicator selection. J Clin Endocrinol Metab 1994;79:204. [48] ODonnell KJ, Rakeman MA, Zhi-Hong D, Xue-Yi C, Mei ZY, DeLong N, et al. Effects of iodine supplementation during pregnancy on child growth and development at school age. Dev Med Child Neurol 2002;44:7681. [49] Todd CH, Dunn JT. Intermittent oral administration of potassium iodide solution for the correction of iodine deciency. Am J Clin Nutr 1998;67(6):127983. [50] Ibrahim M, Sinn J, McGuire W. Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants. Cochrane Database Syst Rev 2006(2):CD005253. [51] Prevention control of iodine deciency in pregnant, lactating women, in children less than 2-years-old: conclusions, recommendations of the Technical Consultation. WHO Secretariat, Andersson M, de Benoist B, Delange F, Zupan J. Public Health Nutr 2007;10(12A):160611.

ARTICLE IN PRESS
92 M.B. Zimmermann / Journal of Trace Elements in Medicine and Biology 22 (2008) 8192

[52] Pennington JA. A review of iodine toxicity reports. J Am Diet Assoc 1990;90:157181. [53] Parsad D, Saini R. Acneform eruption with iodized salt. Int J Dermatol 1998;37:478. [54] Chow CC, Phillips DI, Lazarus JH, Parkes AB. Effect of low dose iodide supplementation on thyroid function in potentially susceptible subjects: are dietary iodide levels in Britain acceptable? Clin Endocrinol 1991;34:4136. [55] Zimmermann MB, Ito Y, Hess SY, Fujieda K, Molinari L. High thyroid volume in children with excess dietary iodine intakes. Am J Clin Nutr 2005;81:8404. [56] European Commission HaCPD-GSCoF. Opinion of the Scientic Committee on Food on the tolerable upper level of intake of iodine. Brussels: European Commission; 2002. [57] Delange F, de Benoist B, Alnwick D. Risks of iodineinduced hyperthyroidism after correction of iodine deciency by iodized salt. Thyroid 1999;9:54556. [58] Corvilain B, Van Sande J, Dumont JE, Bourdoux P, Ermans AM. Autonomy in endemic goiter. Thyroid 1998;8:10713. [59] Yang F, Shan Z, Teng X, Li Y, Guan H, Chong W, et al. Chronic iodine excess does not increase the incidence of hyperthyroidism: a prospective community-based epidemiological survey in China. Eur J Endocrinol 2007; 156(4):4038.

[60] Teng W, Shan Z, Teng X, Guan H, Li Y, Teng D, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med 2006;354(26):278393. [61] Pedersen IB, Laurberg P, Knudsen N, Jrgensen T, Perrild H, Ovesen L, et al. An increased incidence of overt hypothyroidism after iodine fortication of salt in Denmark: a prospective population study. J Clin Endocrinol Metab 2007;92(8):31227. [62] Bu low Pedersen I, Laurberg P, Knudsen N, Jrgensen T, Perrild H, Ovesen L, et al. Increase in incidence of hyperthyroidism predominantly occurs in young people after iodine fortication of salt in Denmark. J Clin Endocrinol Metab 2006;91(10):38304. [63] Sehestedt T, Knudsen N, Perrild H, Johansen C. Iodine intake and incidence of thyroid cancer in Denmark. Clin Endocrinol (Oxf) 2006;65(2):22933. [64] Feldt-Rasmussen U. Iodine and cancer. Thyroid 2001;11(5): 4836. [65] Laurberg P, Nhr SB, Pedersen KM, Hreidarsson AB, Andersen S, Bu low Pedersen I, et al. Thyroid disorders in mild iodine deciency. Thyroid 2000;10(11):95163. [66] Utiger RD. Iodine nutrition more is better. N Engl J Med 2006;354(26):281921. [67] UNICEF. The State of the Worlds Children 2007. Available at: /www.unicef.org/nutrition/les/SOWCO6_ Table2.pdfS. Accessed January 18, 2008.